A comparative study of orphan drug prices in Europe

References

• European Medicines Agency (EMA). Orphan drugs and rare diseases at a glance. [ cited 13 Jul 2016]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Other/2010/01/WC500069805.pdf
   Google Scholar
• NICE. Citizens council report ultra orphan drugs. [ cited 14 Jul 2016]. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1885144/pdf/bcp0062-0264.pdf
   Google Scholar
• Hughes W, Palma A, Schuurman A, et al. Paying for the Orphan Drug System: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments? Orpanet J Rare Dis. 2012;7:1. Available from: http://www.ojrd.com/content/7/1/74
   Web of Science ®Google Scholar
• Simoens S. Pricing and reimbursement of orphan drugs: the need for more transparency. Orphanet J Rare Dis. 2011;6:42.
   PubMed Web of Science ®Google Scholar
• Le Cam Y. Inventory of access and prices of orphan drugs across Europe: a collaborative work between national alliances on rare diseases & EURODIS. Paris (France): EURODIS; 2010.
   Google Scholar
• Heemstra HE. Variations in access and use of orphan drugs among EU member states. Eur J Hosp Pharm Pract. 2010;15(4):25–13.
   Google Scholar
• Denis A, Mergaert L, Fostier C, et al. A comparative study of European rare disease and orphan drug markets. Health Policy. 2010;97:173–179.
   PubMed Web of Science ®Google Scholar
• Gammie T, Lu CY, Babar ZU-D, et al. Access to Orphan Drugs: A Comprehensive Review of Legislations, Regulations and Policies in 35 Countries. Plos ONE. 2015;10(10):e0140002.
   PubMed Web of Science ®Google Scholar
• Toumi M, Rémuzat C, Vataire AL, et al. External reference pricing of medicinal products: simulation based considerations for cross country coordination. 2013. Available from: http://ec.europa.eu/health/healthcare/docs/erp_reimbursement_medicinal_products_en.pdf
   Google Scholar
• Aymé S, Rodwell C, editors. 2012 Report on the state of the art of rare disease activities in Europe of the European Union Committee of experts on rare diseases. Jul 2012. Available from: http://ec.europa.eu/health//sites/health/files/rare_diseases/docs/eucerd2012_report_state_of_art_rare_diseases_activities_5.pdf.
   Google Scholar
• Tordrup D, Tzouma V, Kanavos P. Orphan drug considerations in Health Technology Assessment in eight European countries. Rare Dis Orphan Drugs: Int J Public Health. 2014;1(3):86–97.
   Google Scholar
• Bouslouk M. G-BA benefit assessment of new orphan drugs in Germany: the first five years. Expert Opinion Orphan Drugs. 2016;4(5):453–455. DOI:10.1517/21678707.2016.1166950
   Web of Science ®Google Scholar
• Garau M, Mestre-Ferrandiz J. Access mechanisms for orphan drugs: A comparative study of selected European countries. OHE Breifing. 2009;52:1–32. Available from: https://www.ohe.org/publications/access-mechanisms-orphan-drugs-comparative-study-selected-european-countries.
   Google Scholar
• Festøy H, Ognøy A WHO PPRI pharma profile Norway. Jun 2015. Available from: https://legemiddelverket.no/Documents/English/Price%20and%20reimbursement/PPRI_Pharma_Profile_Norway_20150626_final.pdf
   Google Scholar
• NICE. Interim process and methods of the highly specialised technologies programme. 2013. Available from: https://www.nice.org.uk/Media/Default/About/what-we-do/NICE-guidance/NICE-highly-specialised-technologies-guidance/Highly-Specialised-Technologies-Interim-methods-and-process-statements.pdf
   Google Scholar
• SMC. PACE (Patient & Clinician Engagement) overview document process changes for end of life and very rare conditions (orphan and ultra-orphan medicines). 2013. Available from: https://www.scottishmedicines.org.uk/files/PACE/PACE_Overview_Document_V2.pdf
   Google Scholar
• Drummond M, Towse A. Orphan drug policies: a suitable case for treatment. Eur J Health Econ. 2014;15:335–340.
   PubMed Web of Science ®Google Scholar
• Schlander M, Holm S, Nord E et al. Towards social cost value analyis: the need for new approaches for evaluating drugs for ultra-rare disorders (Urds). Institute for Innovation and Valuation in Health Care. 2015. [ cited Jul 2016]. Available from: http://www.innoval-hc.com/discussion-papers.html
   Google Scholar
• Gutierrez L, Patris J, Hutchings A, et al. Principles for consistent value assessment and sustainable funding of orphan drugs in Europe. Orphanet J Rare Dis. 2015;10:53.
   Web of Science ®Google Scholar
• Schey C, Milanova T, Hutchings A. Estimating the budget impact of orphan medicines in Europe: 2010-2020. Orphanet J Rare Dis. 2011;6:62.
   PubMed Web of Science ®Google Scholar
• Côté A, Keating B. What is wrong with orphan drug policies? Value Health. 2012;15:1185–1191.
   PubMed Web of Science ®Google Scholar
• Simoens S, Cassiman D, Dooms M, et al. Orphan drugs for rare diseases: is it time to revisit their special market access status? Drugs. 2012;72(11):1437–1443.
   PubMed Web of Science ®Google Scholar
• Michel M, Toumi M. Access to orphan drugs in Europe: current and future issues. Expert Rev Pharmacoecon Outcomes Res. 2012;12(1):23–29.
   PubMed Web of Science ®Google Scholar
• Picavet E, Dooms M, Cassiman D, et al. Drugs for rare diseases: influenceof orphan designation status on price. Appl Health Econ Health Policy. 2011;9(4):275–279.
   PubMedGoogle Scholar
• Picavet, Picavet E, Morel T, et al. Shining a light in the black box of orphan drug pricing. Orphanet J Rare Dis. 2014;9:62.
   PubMed Web of Science ®Google Scholar
• IHS PharmOnline International (POLI). [ cited Jun 2016]. Available from: https://www.ihs.com/products/pharmaonline-international.html
   Google Scholar
• Ameli. [ cited Jul 2016]. Available from: http://www.codage.ext.cnamts.fr/codif/bdm_it/index.php?p_site=AMELI
   Google Scholar
• The British National Formulary (BNF). [ cited Jul 2016]. Available from: https://www.medicinescomplete.com/mc/login.htm
   Google Scholar
• Farmadati. [ cited Jul 2016]. Available from: http://www.farmadati.it/
   Google Scholar
• WHO. Child Growth Standards: weight for Age. [ cited Jul 2016]. Available from: http://www.who.int/childgrowth/standards/weight_for_age/en/
   Google Scholar
• Alcimed. Study on orphan drugs. Paris. 2005. Available from: http://ec.europa.eu/health/files/orphanmp/doc/pricestudy/final_final_report_part_1_web_en.pdf
   Google Scholar
• Macarthur D. Orphan drugs in Europe: pricing, reimbursement, funding & market access issues. Justpharmareports. USA: Arrowhead publishers; 2011.
   Google Scholar
• Onakpoya I, Spencer EA, Thompson MJ, et al. Effectiveness, safety and costs of orphan drugs: an evidence-based review. BMJ Open. 2015;5:e007199.
   PubMed Web of Science ®Google Scholar
• Nicod E, Kanavos P. Scientific and social value judgments for orphan drugs in health technology assessment. Int J Technol Assess Health Care. 2016;32(4):1–15.
   Web of Science ®Google Scholar
• European Parliament Directorate-General for Internal Policies. Differences in costs of and access to pharmaceutical products in the EU. 2011. Available from: http://www.europarl.europa.eu/RegData/etudes/etudes/join/2011/451481/IPOL-ENVI_ET(2011)451481_EN.pdf.
   Google Scholar
• European Commission. Study on enhanced cross-country coordination in the area of pharmaceutical product pricing. Luxembourg: Publications Office of the European Union. Dec, 2015. Available from: http://ec.europa.eu/health/sites/health/files/systems_performance_assessment/docs/pharmaproductpricing_frep_en.pdf.
   Google Scholar
• Sussex J, Rollet P, Garau M, et al. A pilot study of multicriteria decision analysis for valuing orphan medicines. Value Health. 2013;16:1163–1169.
   PubMed Web of Science ®Google Scholar
• Paulden M, Stafinski T, Menon D, et al. Value-based reimbursement decisions for orphan drugs: a scoping review and decision framework. Pharmacoeconomics. 2015;33:255–269.
   PubMed Web of Science ®Google Scholar
• Wagner M, Khoury H, Willet J, et al. Can the EVIDEM framework tackle issues raised by evaluating treatments for rare diseases: analysis of issues and policies, and context-specific adaptation. Pharmacoeconomics. 2016;34:285–301.
   PubMed Web of Science ®Google Scholar
• Palaska C, Hutchings A. Value assessment and pricing frameworks for rare disease treatments: new approaches from the literature. ISPOR 18th Annual European Congress; Nov 2015; Milan, Italy. Available from: http://www.ispor.org/research_pdfs/51/pdffiles/PSY113.pdf
   Google Scholar
• Fellows GK, Hollis A. Funding innovation for treatment for rare diseases: adopting a cost-based yardstick approach. Orphanet J Rare Dis. 2013;8:18044.
   Web of Science ®Google Scholar
• US Forex Foreign Exchange Services. [ cited Oct 2016]. Available from: http://www.usforex.com/forex-tools/historical-rate-tools/yearly-average-rates
   Google Scholar